A new study reports that hematologic abnormalities may occur in one-third of infants exposed to natalizumab during the third trimester but treatment was generally safe (Triplett et al. Mult Scler Relat Disord 2020;40:101961). Read More
A number of new drugs for neurology and psychiatry are currently in review with regulatory authorities in the U.S. and Canada. The following summarizes some of the key therapies expected to be approved in 2020. Read More
The U.S. Food and Drug Administration has granted Expanded Access to methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), enabling some patients to undergo treatment before the drug is formally authorized. MDMA, known by the street names Ecstasy and Molly, was developed and patented by E. Merck (now EMD Serono) a century ago. It was used as an empathogen in psychotherapy during the 1970s but was labelled as a Schedule I controlled substance (no medical use) in 1985.
A 30-year follow-up of patients with clinically isolated syndrome (CIS) reports that MRI findings (lesion location, lesion number) at baseline and at one year were the most robust prognostic factors of long-term outcomes (Chung et al. Ann Neurol 2020;87:63-74). Results at 20 years were previously published as Fisniku et al. Brain 2008;131:808-817.